These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8095749)

  • 21. [Modified dithranol minute therapy of psoriasis vulgaris].
    Chlebarov S; Rauh M
    Z Hautkr; 1988 Aug; 63(8):658-62. PubMed ID: 3188606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased high-affinity epidermal growth factor receptors in psoriatic epidermis.
    Urano Y; Ikeuchi T; Fujimoto A; Asano T; Arase S; Shigemi F; Takeda K
    Tokushima J Exp Med; 1989 Dec; 36(3-4):53-8. PubMed ID: 2636999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calmodulin inhibition by anthralin? Investigations in vitro and in vivo.
    Wollina U; Klinger R; Wetzker R; Knopf B
    Dermatologica; 1989; 179(2):61-3. PubMed ID: 2529149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of proliferation of HeLa cells by dithranol (anthralin) and 1o-butyryl dithranol (butantrone).
    Remitz A; Kariniemi AL; Lehtonen E; Nordling S
    Br J Dermatol; 1989 Apr; 120(4):525-31. PubMed ID: 2730843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone).
    Mustakallio KK; Brandt H
    Acta Derm Venereol; 1984; 64(1):63-6. PubMed ID: 6203285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-contact therapy for psoriasis with 3.9% butantrone (10-butyryl dithranol).
    Remitz A
    Acta Derm Venereol; 1989; 69(4):351-4. PubMed ID: 2568062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells.
    Hollywood KA; Winder CL; Dunn WB; Xu Y; Broadhurst D; Griffiths CE; Goodacre R
    Mol Biosyst; 2015 Aug; 11(8):2198-209. PubMed ID: 26018604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes.
    Reichert U; Jacques Y; Grangeret M; Schmidt R
    J Invest Dermatol; 1985 Feb; 84(2):130-4. PubMed ID: 2578530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential of the essential fatty acid-deficient hairless rat as a psoriasis screening model for topical anti-proliferative drugs.
    Jensen M; Groth L; Hølmer G; Hansen HS; Fullerton A
    Skin Pharmacol Appl Skin Physiol; 2002; 15(6):401-13. PubMed ID: 12476014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsoriatic drug anthralin induces EGF receptor phosphorylation in keratinocytes: requirement for H(2)O(2) generation.
    Peus D; Beyerle A; Vasa M; Pott M; Meves A; Pittelkow MR
    Exp Dermatol; 2004 Feb; 13(2):78-85. PubMed ID: 15009100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of the treatment of psoriasis with dithranol in comparison with a combination of dithranol and a corticosteroid].
    Gloor M; Graf R; Wirth H; Landau M
    Hautarzt; 1983 Oct; 34(10):500-3. PubMed ID: 6643055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.
    Yamamoto T; Nishioka K
    Skin Pharmacol Appl Skin Physiol; 2003; 16(1):50-8. PubMed ID: 12566829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dithranol downregulates expression of Id1 mRNA in human keratinocytes in vitro.
    Ronpirin C; Tencomnao T
    Genet Mol Res; 2012 Sep; 11(3):3290-7. PubMed ID: 23079823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The response of normal human skin to single and repeated applications of dithranol cream: an immunohistochemical assessment.
    Swinkels OQ; Prins M; Birker LW; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2002; 15(4):262-9. PubMed ID: 12218288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha.
    Yoshida A; Kanno H; Watabe D; Akasaka T; Sawai T
    Arch Dermatol Res; 2008 Jan; 300(1):37-45. PubMed ID: 17960400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). II. Clinical comparison of dithranol and butantrone sticks with special reference to side effects.
    Brandt H
    Acta Derm Venereol; 1987; 67(1):55-61. PubMed ID: 2436415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation of mouse epidermal 12-lipoxygenase by anthralin--implications for the role of oxygen radicals.
    Müller K; Gawlik I
    Biochem Pharmacol; 1996 May; 51(9):1173-9. PubMed ID: 8645340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dithranol on neutrophil superoxide generation in patients with psoriasis.
    Kavanagh GM; Burton JL; Donnell VO
    Br J Dermatol; 1996 Feb; 134(2):234-7. PubMed ID: 8746335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The response of uninvolved skin of patients with psoriasis to single and repeated applications of dithranol cream: an immunohistochemical assessment.
    Swinkels OQ; Prins M; van Vlijmen-Willems IM; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2002; 15(6):385-92. PubMed ID: 12476012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of dithranol and butantrone in short contact therapy of psoriasis.
    Göransson A
    Acta Derm Venereol; 1987; 67(2):149-53. PubMed ID: 2438880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.